Attracting Support from Leading, Enthusiastic Investors
Our extensive expertise in exosome science, our best-in-class exosome technology platform and our multi-pronged strategy for building value have attracted support from prestigious investors. Our financial partners share our belief and enthusiasm in the tremendous potential of Exosome Diagnostics to transform the molecular diagnostics landscape, deliver on the promise of personalized precision medicine, and improve patients’ lives.
Successful Series A and Series B Rounds
We have raised nearly $80 million in financings thus far from leading investors during our Series A and Series B rounds, including Forbion Capital Partners, NGN Capital, Arcus Ventures, Tiger Management, Blue Ridge Capital, QIAGEN, and CD Ventures.
To learn more, please contact firstname.lastname@example.org.